

(19)



(11)

EP 2 299 271 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Claims DE 1
Claims EN 1
Claims FR 1

(51) Int Cl.:

A23L 1/221 (2006.01)	A23L 1/48 (2006.01)
C07K 5/02 (2006.01)	A23L 1/22 (2006.01)
G01N 33/566 (2006.01)	A23L 1/305 (2006.01)
C07K 5/00 (2006.01)	G01N 33/68 (2006.01)

(48) Corrigendum issued on:

26.02.2014 Bulletin 2014/09

(45) Date of publication and mention of the grant of the patent:

10.07.2013 Bulletin 2013/28

(21) Application number: **10012901.4**

(22) Date of filing: **08.11.2006**

(54) **Kokumi-imparting compositions**

Kokumi verleihende Zusammensetzungen
 Compositions de distribution de Kokumi

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **09.11.2005 JP 2005325300**

22.11.2005 US 738562 P

07.07.2006 JP 2006188458

20.07.2006 US 807831 P

(43) Date of publication of application:

23.03.2011 Bulletin 2011/12

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

09007706.6 / 2 175 273

06823396.4 / 1 946 110

(73) Proprietor: **Ajinomoto Co., Inc.**

Tokyo
104-8315 (JP)

(72) Inventors:

- **Ohsu, Takeaki**
Kawasaki-shi
Kanagawa 210-8681 (JP)

- **Takeshita, Sen**
Kawasaki-shi
Kanagawa 210-8681 (JP)
- **Eto, Yuzuru**
Kawasaki-shi
Kanagawa 210-8681 (JP)
- **Amino, Yusuke**
Kawasaki-shi
Kanagawa 210-8681 (JP)
- **Miyamura, Naohiro**
Kawasaki-shi
Kanagawa 210-8681 (JP)
- **Yamanaka, Tomohiko**
Kawasaki-shi
Kanagawa 210-8681 (JP)
- **Nagasaki, Hiroaki**
Kawasaki-shi
Kanagawa 210-8681 (JP)

(74) Representative: **Strehl Schübel-Hopf & Partner**
Maximilianstrasse 54
80538 München (DE)

(56) References cited:

EP-A1- 1 554 939 WO-A2-01/51629
JP-A- 7 188 282

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 299 271 B9

Description

Technical Field

5 **[0001]** This application claims priority from Japanese Patent Application No. 2005-325300 filed on November 9, 2005, Japanese Patent Application No. 2006-188458 filed on July 7, 2006, US Provisional Patent Application No. 60/738562 filed on November 22, 2005, US Provisional Patent Application No. 60/807831 filed on July 20, 2006.

[0002] The present invention relates to the use of compounds to impart kokumi on a food or drink.

10 Background Art

[0003] The calcium receptor is also called the calcium sensing receptor (CaSR), and is a receptor consisting of 1078 amino acids, and is classified into the class C of seven-transmembrane receptors (G protein-coupled receptor; GPCR). Cloning of the gene for this calcium receptor was reported in 1993 (Non-patent document 1), and it is known to cause various cell responses through elevation of intracellular calcium level etc., when it is activated with calcium etc. The gene sequence of the human calcium receptor is registered with GenBank Accession No. NM_000388, and is well conserved in animals.

15 **[0004]** The aforementioned calcium receptor may act to promote or suppress biological functions. Therefore, at present, therapeutic agents which may act as activators and inhibitors of the calcium receptor are appropriately used in the treatment of neurological diseases, hepatic diseases, cardiovascular diseases, digestive system diseases, and other diseases, depending on pathological conditions. For example, the calcium receptor is able to detect increased blood calcium level in the parathyroid, and suppress secretion of the parathyroid hormone (PTH) to correct the blood calcium level. Therefore, an effect of reducing the blood calcium level is expected for a calcium receptor activator. It has been actually clarified that when a calcium receptor activator is used to treat secondary hyperparathyroidism in a hemodialysis patient, it reduces the PTH level without elevating the calcium and phosphorus levels.

20 **[0005]** Since functional analysis of the calcium receptor has been conducted mainly for calcium homeostasis, the applied researches therefore are so far mainly concerned bone metabolic diseases in which calcium regulation is involved. However, it has become clear that the calcium receptor is widely distributed in living bodies other than the parathyroid and kidney from the results of genetic expression analyses etc. (Non-patent documents 2 and 3), and possibilities thereof for being involved in various biological functions and causes of diseases have been proposed. For example, it is estimated that the calcium receptor is involved in the functions of the liver, heart, lung, alimentary canal, lymphocyte, and pancreas. The inventors of the present invention also have confirmed that it is expressed in a wide range of tissues in living bodies by analyses based on RT-PCR using RNAs extracted from rat tissues. From the aforementioned viewpoints, the values of activators and inhibitors of the calcium receptor are presently rapidly increasing for applications.

25 **[0006]** Moreover, other than calcium, cations such as gadolinium cation, basic peptides such as polyarginine, polyamine such as spermine, amino acids such as phenylalanine, and so forth have been reported as calcium receptor activators (Non-patent document 4).

30 **[0007]** Although many specific activators have been developed so far as calcium receptor activators as described above, there are few compounds existing in living bodies among them, and the activities of the compounds existing in living bodies are very low. Therefore, therapeutic agents for various diseases containing these activators have serious problems concerning side reaction, permeability and activity. For example, although it is known that amino acids act on the calcium receptors, it is considered that actual application thereof as the activators is difficult since the activity is very weak. Moreover, although macromolecules such as polyarginine have been reported as the activator as described above, it is estimated that the functions are based on the actions as polyvalent cations having irregular structures. That is, it is not known that a peptide having a specific structure is useful as a calcium receptor activator.

35 **[0008]** Meanwhile, in the field of foodstuffs, taste substances have been applied for many years. In particular, substances having the five basic tastes, namely, sweet taste, salty taste, sour taste, bitter taste, and umami (delicious taste), and substances enhancing these have widely been used as seasonings. As a concept of taste that cannot be expressed with the aforementioned tastes, there is "kokumi". Kokumi means a taste that cannot be expressed with the five basic tastes, and means a taste that enhances not only the basic tastes but also marginal tastes of the basic tastes, such as thickness, growth (mouthfulness), continuity, and harmony. Several methods for imparting kokumi have been reported so far, and glutathione (Patent document 1), heated products of gelatin and tropomyosin (Patent document 2), sulfone group-containing compounds (Patent document 3), a peptide containing the Asn-His sequence (Patent document 4), and so forth have been reported.

40 **[0009]** Although development of various kokumi-imparting substances has been attempted as described above, and commercialization has been made mainly for extracts of natural products, there are presently very few examples of isolation of a pure kokumi component from an extract of natural product, such as glutathione and N-(4-methyl-5-oxo-1-imidazolin-2-yl)sarcosine.

[0010] Therefore, the development of highly effective, safe and inexpensive kokumi-imparting substances is desired, and a convenient and highly sensitive method for screening for a kokumi-imparting substance is needed for that purpose.

[Non-patent document 1] Nature, 1993 Dec 9;366(6455):575-80

[Non-patent document 2] J. Endocrinol., 2000 May, 165(2):173-7

5 [Non-patent document 3] Eur. J. Pharmacol., 2002 Jul. 5, 447(2-3):271-8

[Non-patent document 4] Cell Calcium., 2004 Mar., 35(3):209-16

[Patent document 1] Japanese Patent No. 1464928

[Patent document 2] Japanese Patent Laid-open Publication (KOKAI) No. 10-276709

[Patent document 3] Japanese Patent Laid-open Publication (KOKAI) No. 8-289760

10 [Patent document 4] WO2004/096836

[0011] WO 01/51629 A2 discloses circularly permuted proteins in which the tripeptide Gly-Arg-Glu affects the interaction-dependent activity.

[0012] JP 7 188282 A discloses tripeptides which have the activity of inhibiting the enzymes transforming angiotensin.

[0013] EP 1 554 939 A1 discloses tripeptides capable of imparting kokumi.

15

Disclosure of Invention

[Problems to be solved by the Invention]

20 **[0014]** An object of the present invention is to provide the use of compounds to impart kokumi on a food or drink.

[Means for solving the Problems]

25 **[0015]** As a result of a search of activators of the calcium receptor, the inventors of the present invention found that low molecular peptides, including glutathione, are able to activate the calcium receptor. Moreover, since glutathione is known to be a kokumi-imparting substance, they evaluate whether the low molecular peptides as activators of the calcium receptor imparted kokumi, and found that the low molecular peptides imparted kokumi. The present invention was accomplished on the basis of these findings.

[0016] The present invention provides the following.

30

(1) The use of a composition comprising one or more compounds selected from the group consisting of γ -Glu-Val-Y, wherein Y is selected from the group consisting of Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys, and Gln, γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys (S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu and γ -Glu-Cys(S-Me), and combinations thereof, to impart kokumi on a food or drink.

35

(2) The use as described in (1), wherein said compound is γ -Glu-Val-Gly.

40

(3) The use as described in (1) or (2), wherein said one or more compounds are added to a food or drink at a concentration of 0.0001 to 0.1%.

(4) The use as described in any one of (1) to (3),

45

wherein a composition comprising at least one other compound having calcium receptor activation activity selected from calcium, protamine, polyarginine, spermine, polylysine, glutathione and cinacalcet is additionally added.

Effect of the Invention

50 **[0017]** According to the present invention, a highly effective, safe and inexpensive kokumi-imparting composition is provided.

Brief Description of the Drawings

55 **[0018]**

[Fig. 1] Drawing showing an action of calcium on the calcium receptor.

The human calcium receptor cRNA was introduced into *Xenopus laevis* oocytes by microinjection. Recorded were

values of intracellular response currents which flew when a calcium chloride solution was added at an arbitrary concentration. The maximum values of intracellular currents were considered response current values. It was confirmed that no response was observed in oocytes introduced with distilled water by microinjection as a control.

[Fig. 2] Drawing showing an action of L-amino acids on the calcium receptor.

The human calcium receptor cRNA was introduced into *Xenopus laevis* oocytes by microinjection. Recorded were values of intracellular response currents which flew when a 10 mM L-amino acid solution was added. The maximum values of intracellular currents were considered response current values. It was confirmed that no response was observed in oocytes introduced with distilled water by microinjection as a control.

[Fig. 3] Drawing showing an action of D-amino acids on the calcium receptor.

The human calcium receptor cRNA was introduced into *Xenopus laevis* oocytes by microinjection. Recorded were values of intracellular response currents which flew when a 10 mM D-amino acid solution was added. The maximum values of intracellular currents were considered response current values. It was confirmed that no response was observed in oocytes introduced with distilled water by microinjection as a control.

[Fig. 4] Drawing showing an action of peptides on the calcium receptor.

The human calcium receptor cRNA was introduced into *Xenopus laevis* oocytes by microinjection. Recorded were values of intracellular response currents which flew when a peptide solution was added at an arbitrary concentration. The maximum values of intracellular currents were considered response current values. It was confirmed that no response was observed in oocytes introduced with distilled water by microinjection as a control.

Best Mode for Carrying Out the Invention

[0019] Hereafter, the present invention will be explained in detail.

[0020] In this specification, the "calcium receptor" is also called the calcium sensing receptor (CaSR), and belongs to the class C of seven-transmembrane receptors. In this specification, the "calcium receptor activity" means binding to the aforementioned calcium receptor to activate the guanine nucleotide binding protein and thereby transmit signals. Furthermore, in this specification, the "calcium receptor activator" is a substance that acts on the aforementioned calcium receptor to activate the calcium receptor and control the functions of cells expressing the calcium receptor.

[0021] In this specification, "kokumi" means a taste that cannot be expressed by the five basic tastes, sweet taste, salty taste, sour taste, bitter taste, and umami, in which, not only the basic tastes, marginal tastes of the basic tastes, such as thickness, growth (mouthfulness), continuity, and harmony are enhanced. Further, the "kokumi-imparting agent" or "kokumi-imparting substance" refers to an agent or substance that can enhance the five basic tastes, sweet taste, salty taste, sour taste, bitter taste, and umami, and impart marginal tastes of the basic tastes, such as thickness, growth (mouthfulness), continuity, and harmony accompanying the basic tastes. Therefore, the kokumi-imparting composition used in the present invention can also be used as a sweet taste-enhancing agent, salty taste-enhancing agent, sour taste-enhancing agent, bitter taste-enhancing agent, or umami-enhancing agent. As for intensity of kokumi, "first and middle taste" means taste that is felt during the period of 0 to 4 seconds after eating, and "aftertaste" means taste that is felt after 5 seconds following eating.

[0022] In this specification, all the amino acids and amino acid residues constituting the peptides are L-isomers, unless otherwise specified.

<1> Method for screening for kokumi-imparting substance

[0023] The method for screening for a kokumi-imparting substance used in the present invention (henceforth also referred to as the screening method) is characterized by using the calcium receptor activity as an index. Specifically, the screening method comprises the first step of reacting a calcium receptor and a test substance and detecting calcium receptor activity, and the second step of measuring the kokumi-imparting effect of the test substances for which calcium receptor activation activity is detected in the first step.

[0024] The specific process steps of the screening method are exemplified below. However, the steps of the screening method are not limited to these steps.

1) A test substance is added to a calcium receptor activity measurement system for measuring the calcium receptor activity, and the calcium receptor activity is measured.

2) The calcium receptor activity obtained with adding the test substance and the calcium receptor activity obtained without adding the test substance are compared.

3) A test substance showing a higher calcium receptor-stimulating activity when the test substance is added is chosen.

4) The kokumi-imparting effect of the chosen test substance is measured, and a test substance having a kokumi-imparting effect is chosen.

[0025] The calcium receptor activity is measured by using, for example, a measurement system using cells expressing the calcium receptor. The cells may be cells endogenously expressing the calcium receptor, or recombinant cells introduced with a foreign calcium receptor gene. As the aforementioned calcium receptor activity measurement system, any system may be used without particular limitation so long as chosen is a system with which when an extracellular ligand (activator) specific to the calcium receptor is added to the cells expressing the calcium receptor, binding (reaction) of the activator and the calcium receptor can be detected, or a detectable signal is transmitted into cells in response to binding (reaction) of the activator and the calcium receptor. When the reaction of tested compound result calcium receptor activity; such tested compound are determined as having calcium receptor activation activity and kokumi-imparting compound.

[0026] The aforementioned kokumi-imparting effect can be confirmed by a taste test by a human, or the like. Furthermore, the test substance used for the screening is not particularly limited, and low molecular compounds, saccharides, peptides, proteins, and so forth can be used.

[0027] As the aforementioned calcium receptor, the human calcium receptor encoded by the human calcium receptor gene registered with GenBank Accession No. NM_000388 can be exemplified as a preferred example. In addition, the calcium receptor is not limited to the protein encoded by the gene of the aforementioned sequence, and it may be a protein encoded by a gene having a homology of 60% or more, preferably 80% or more, more preferably 90% or more, to the aforementioned sequence, so long as the protein has the calcium receptor function. The GPRC6A receptor and the 5.24 receptor are also known as subtypes of the calcium receptor, and they can be used for the present invention. The calcium receptor function can be examined by expressing a gene of interest in a cell and measuring changes in the electric current, or intracellular calcium ion concentration at the time of the addition of calcium.

[0028] The origin of the calcium receptor is not particularly limited, and examples include, besides the aforementioned human calcium receptor, calcium receptors derived from animals such as mouse, rat, and dog.

[0029] As described above, the calcium receptor activity can be confirmed by using live cells which express a calcium receptor or a fragment thereof, cell membranes which express a calcium receptor or a fragment thereof, an in vitro system containing a protein of a calcium receptor or a fragment thereof, or the like.

[0030] An example using live cells is shown below. However, confirmation of the calcium receptor activity is not limited to this example.

[0031] The calcium receptor can be expressed in cultured cells such as *Xenopus laevis* oocytes, hamster ovarian cells, and human fetal kidney cells. The calcium receptor can be expressed by cloning a calcium receptor gene in a plasmid that can contain a foreign gene and introducing the plasmid or cRNA obtained by using the plasmid as a template. To detect the reaction, electrophysiological techniques, fluorescent indicator reagents that indicate elevation of intracellular calcium level, and so forth, can be used.

[0032] Expression of the calcium receptor is first confirmed based on the response to calcium or a specific activator. Oocytes that showed intracellular current with calcium at a concentration of about 5 mM or cultured cells that showed fluorescence of the fluorescent indicator reagent with calcium at a concentration of about 5 mM are used. Calcium concentration dependency is determined by changing the calcium concentration. Then, a test substance such as a peptide is prepared to a concentration of about 1 μ M to 1 mM, and added to the oocytes or cultured cells, and the calcium receptor activity of the test substance such as the aforementioned peptide is measured.

<2> Kokumi-imparting agent

[0033] The kokumi-imparting composition used in the present invention comprises a kokumi-imparting substance obtainable by the screening method of the present invention as an active ingredient. The kokumi-imparting agent of the present invention contains, for example, one or more kinds of substances selected from γ -Glu-X-Gly (X represents an amino acid or amino acid derivative except for Cys), γ -Glu-Val-Y (Y represents an amino acid or amino acid derivative), γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys(S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu and γ -Glu-Cys(S-Me) (henceforth also referred to as "peptides and amino acids used for the present invention") as an active ingredient. These peptides and amino acids can also be obtained by the screening method mentioned above. Here, "amino acid" means, but not limited to, neutral amino acids such as Gly, Ala, Val, Leu, Ile, Ser, Thr, Cys, Met, Asn, Gln, Pro and Hyp, acidic amino acids such as Asp and Glu, basic amino acids such as Lys, Arg and His, aromatic amino acids such as Phe, Tyr, Trp, and other amino acids such as Homoserine, Citrulline, Ornithine, alpha-Aminobutylic acid, Norvaline, Norleucine and Taurine.


[0034] In the present specification, abbreviations for amino acid residues are as follows:

- (1) Gly: Glycine
- (2) Ala: Alanine
- (3) Val : Valine

- (4) Leu: Leucine
 (5) Ile: Isoleucine
 (6) Met: Methionine
 (7) Phe: Phenylalanine
 5 (8) Tyr: Tyrosine
 (9) Trp: Trptophan
 (10) His: Histidine
 (11) Lys: Lysine
 (12) Arg Arginine
 10 (13) Ser: Serine
 (14) Thr: Threonine
 (15) Asp: Aspartic acid
 (16) Glu: Glutamic acid
 (17) Asn: Asparagine
 15 (18) Gln: Glutamine
 (19) Cys: Cysteine
 (20) Pro: Proline
 (21) Orn: Ornithine
 (22) Sar: Sarcosine
 20 (23) Cit: Citruline
 (24) N-Val: Norvaline
 (25) N-Leu: Norleucine
 (26) Abu: alpha-Aminobutylic acid
 (27) Tau: Taurine
 25 (28) Hyp: Hydroxyproline
 (29) t-Leu: tert-leucine

[0035] Further, "amino acid derivative" means various types of derivative of above-mentioned amino acids, those can be exemplified as, but not limited to, unusual amino acids, non-natural amino acids, amino alcohols, substituted amino acids of which amino acid side chain, such as carbonyl group, amino group and thiol group, is substituted with various substituents. Such substituents include alkyl group, acyl group, hydroxyl group, amino group, alkylamino group, nitro group, sulfonyl group and various protection groups. Such substituted amino acids include, for example, Arg (NO₂): N- γ -nitro arginine, Cys (SNO): S-nitrocysteine, Cys (S-Me): S-methyl cysteine, Cys (S-allyl): S-allyl cysteine, Val-NH₂: valinamide, Val-ol: valinol (2-amino-3-methyl-1-butanol).

[0036] In the present specification, γ -Glu-Cys(SNO)-Gly has the following structural formula, and the "(O)" in the formulas γ -Glu-Met(O) and γ -Glu-Cys(S-Me)(O) indicates a sulfoxide structure. The " γ " in the formulas γ -Glu indicates that glutamic acid bonds to another amino acid via γ position of carboxy group in the glutamic acid.



S-Nitrosoglutathione (GNSO)

[0037] γ -Glu-X-Gly (X represents an amino acid or amino acid derivative except for Cys), γ -Glu-Val-Y (Y represents an amino acid or amino acid derivative), γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-

Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys(S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu, and γ -Glu-Cys(S-Me) impart kokumi. Therefore, γ -Glu-X-Gly (X represents an amino acid or amino acid derivative except for Cys), γ -Glu-Val-Y (Y represents an amino acid or amino acid derivative), γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys(S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu and γ -Glu-Cys(S-Me) can be used as kokumi-imparting agents. The peptides and amino acids used for the present invention may be independently used, or can be used as a mixture of arbitrary two or more kinds of them. Among these, compounds having a structural formula γ -Glu-Val-Y (Y represents Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys, or Gln) are preferred.

[0038] Although threshold concentrations (minimum concentrations allowing sensing of taste) of known taste peptides are about 0.2% (1/10 of threshold concentration of MSG), and thus their practicality is poor (J. Agr. Food Chem., vol. 23, No. 1, 49-53 (1975)), the compounds used in the present invention show kokumi enhancing activity from an extremely low concentration of about 0.0001 to 0.1%, and thus they are extremely useful compounds which have extremely high activity.

[0039] As the aforementioned peptides and amino acids used for the present invention, if they are available as commercial products, those can be used. Furthermore, the peptides can be obtained by suitably using a known technique such as (1) a method of chemically synthesizing them, or (2) a method of synthesizing them by an enzymatic reaction. Since the number of residues of the contained amino acid residues of the peptides used for the present invention is as comparatively small as 2 or 3 residues, a method of chemically synthesizing them is convenient. When chemically synthesizing them, the oligopeptides can be synthesized or half-synthesized by using a peptide synthesizer. Examples of the method of chemically synthesizing them include, for example, a peptide solid phase synthetic method. Peptides synthesized as described above can be purified by usual means, for example, ion exchange chromatography, reversed phase high performance liquid chromatography, affinity chromatography, and so forth. Such a peptide solid phase synthetic method and the following purification of peptide are well known in this technical field.

[0040] Furthermore, the peptides used for the present invention can also be prepared by an enzymatic reaction. For example, the method described in International Patent Publication W02004/011653 can be used. That is, they can also be prepared by reacting one amino acid or dipeptide of which carboxyl terminus is esterified or amidated and an amino acid having a free amino group (for example, an amino acid of which carboxyl group is protected) in the presence of a peptide producing enzyme, and purifying the produced dipeptide or tripeptide. Examples of the peptide producing enzyme include a culture of microorganisms having an ability to produce peptides, microbial cells separated from such culture, processed product of cells of such microorganisms, peptide producing enzymes derived from such microorganisms, and so forth.

[0041] The peptides and amino acids used for the present invention also include those in the form of a salt. When the peptides and amino acids used for the present invention are in the form of a salt, they may be pharmacologically acceptable salts. Examples of a salt with an acidic group such as a carboxyl group in the formula include ammonium salts, salts with alkali metals such as sodium, and potassium, salt with alkaline earth metals such as calcium, and magnesium, aluminum salts, zinc salts, salts with organic amines such as triethylamine, ethanolamine, morpholine, pyrrolidine, piperidine, piperazine, and dicyclohexylamine, and salts with basic amino acids such as arginine, and lysine. Examples of salts with a basic group in case that a basic group exists in the formula include salts with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, and hydrobromic acid, salts with organic carboxylic acids such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid, tannic acid, butyric acid, hibenzoic acid, pamoic acid, enanthoic acid, decanoic acid, teoclic acid, salicylic acid, lactic acid, oxalic acid, mandelic acid, and malic acid, and salts with organic sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.

[0042] The method for using kokumi-imparting substances obtained by the screening method and kokumi-imparting agents containing one or more kinds of substances selected from the peptides and amino acids used for the present invention as an active ingredient is not particularly limited, and they can be used by adding them to food or drink such as seasonings, foods, and drinks.

[0043] The kokumi-imparting substances obtained by the screening method can be used by adding to food or drink such as seasonings, foods, and drinks independently or in combination with other various additives etc..

[0044] Further, the kokumi-imparting composition used in the present invention may consist of, for example, only one or more kinds of substances selected from the aforementioned peptides and amino acids used for the present invention; further, it may also be constituted with other existing compounds having kokumi-imparting activity (such as glutathione and alliin) or other various additives etc. arbitrarily added. Moreover, the kokumi-imparting agent used in the present invention may contain one or more kinds of existing compounds having calcium receptor activation activity.

[0045] Examples of the aforementioned existing compounds having calcium receptor activation activity include cations such as calcium and gadolinium cations, basic peptides such as polyarginine and polylysine, polyamines such as putrescine, spermine and spermidine, proteins such as protamine, amino acids such as phenylalanine and glutathione, cinacalcet, and so forth. These compounds can also be in any acceptable salt form thereof. By the way, it was found by

the present inventors that glutathione has calcium receptor activation activity.

[0046] Also, the present inventors have also found that kokumi-imparting activities of those existing compounds having kokumi-imparting activity such as glutathione as well as the kokumi-imparting agent used in the present invention can also be improved when formulated in a composition with compounds having calcium receptor activation activity.

[0047] As the aforementioned additives, any of those known to be able to be added and mixed with food or drink such as seasonings, foods, and drinks can be used without particular limitation. Examples of such additives include, for example, perfumes, saccharides, sweeteners, dietary fibers, vitamins, amino acids such as sodium glutamate (MSG), nucleic acids such as inosine monophosphate (IMP), inorganic salts such as sodium chloride, water, and so forth.

[0048] The amount of the kokumi-imparting substance which is obtained in the screening method or the kokumi-imparting agent used with respect to food or drink may be an amount effective for imparting kokumi, and it is suitably adjusted depending on the purpose. However, it is for example, in the case of seasoning, food, or drink, it may be 1 mass ppb to 99.9 mass %, preferably 10 mass ppb to 99.9 mass %, more preferably 10 mass ppm to 10 mass % with respect to the seasoning, foodstuff, or drink, in terms of the total amount of the kokumi-imparting agent used in the present invention, or kokumi-imparting substance.

[0049] Therefore, by adding one or more kinds of the kokumi-imparting substances obtained by the screening method or the kokumi-imparting agents used in the present invention to food or drink so that the food or drink should contain approximately 1 mass ppb to 99.9 mass %, preferably 10 mass ppb to 99.9 mass %, more preferably 10 mass ppm to 10 mass % of the substances or agents, food or drink imparted with kokumi can be produced.

[0050] Furthermore, food or drink imparted with kokumi can also be prepared by adding a seasoning containing 1 mass ppb to 99.9 mass % of one or more kinds of the kokumi-imparting substances obtained by the screening method or the kokumi-imparting agents used in the present invention to food or drink so that the food or drink should contain 0.01 to 10 mass %, preferably 0.1 to 10 mass %, of the seasoning.

[0051] Form of the kokumi-imparting substance obtained by the screening method or the kokumi-imparting agent used in the present invention at the time of adding it to food or drink may be dry powder, paste, solution, or the like, and the physical properties thereof are not particularly limited.

Examples

[0052] Hereafter, the present invention will be more specifically explained with reference to examples.

<Example 1>

<Preparation of gene (cRNA) >

[0053] The gene of the calcium receptor was prepared as follows. On the basis of the DNA sequence registered at NCBI (calcium receptor: NM_000388), synthetic oligo DNAs (forward primer (N) and reverse primer (C)) used for PCR were designed (Table 1, SEQ ID NOS: 1 and 2).

Table 1

Synthetic oligo DNAs (forward primer (N) and reverse primer (C), h: human)

Code	Sequence(5'-3')
hCASR_N	ACTAATACGACTCACTATAGGGACCATGGCATTATAGCTGCTGCTGG
hCASR_C	TTATGAATTCACCTACGTTTTCTGTAAACAG

[0054] By using human kidney cDNA (Clontech) as a material, the primers shown in Table 1 (hCASR_N (SEQ ID NO: 1) and hCASR_C (SEQ ID NO: 2)) were synthesized, and PCR was performed by using Pfu ultra DNA Polymerase (Stratagene) under the following conditions. After a reaction at 94°C for 3 minutes, a cycle of reactions at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 2 minutes was repeated 35 times, and then a reaction was performed at 72°C for 7 minutes. Whether amplification was attained by PCR was detected by performing agarose electrophoresis, staining with a DNA staining reagent, and ultraviolet irradiation. The chain lengths of the PCR products were confirmed by comparison with DNA markers of known sizes simultaneously subjected to the electrophoresis. The plasmid vector pBR322 (Takara) was digested with the restriction enzyme EcoRV. The gene fragment amplified by PCR was ligated to the cleavage site of the plasmid by using Ligation Kit (Promega). The *Escherichia coli* DH5 α strain was transformed with each ligation reaction solution, and a transformant harboring the plasmid in which the PCR amplification product was cloned was selected. The PCR amplification product was confirmed by DNA sequence analysis. By using this recombinant plasmid as a template together with a cRNA preparation kit (Ambion), cRNA of the calcium receptor gene

was prepared.

<Example 2>

5 <Preparation of various samples>

[0055] As L-amino acid samples, 23 kinds of special grade amino acids, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine (all of these from Ajinomoto), and hydroxyproline (Nakarai Tesque), were used. As D-Cys and D-Trp (Nakarai Tesque) and calcium chloride, those of special grade were used. Furthermore, as peptide samples, γ -Glu-Cys-Gly (Sigma Aldrich Japan), γ -Glu-Cys(SNO)-Gly (Dojin Chemical Laboratory), γ -Glu-Ala (Bachem Feinchemikalien AG), γ -Glu-Gly (Bachem Feinchemikalien AG), γ -Glu-Cys (Sigma Aldrich Japan), γ -Glu-Met (Bachem Feinchemikalien AG), γ -Glu-Abu-Gly (Abu: α -aminobutyric acid, Bachem Feinchemikalien AG), γ -Glu-Thr (Kokusai Chemical), γ -Glu-Val (Kokusai Chemical), γ -Glu-Leu (contract manufactured product), γ -Glu-Ile (contract manufactured product), γ -Glu-Orn (Kokusai Chemical), Asp-Gly (contract manufactured product), Cys-Gly (contract manufactured product), Cys-Met (contract manufactured product), Glu-Cys (contract manufactured product), Gly-Cys (contract manufactured product), Leu-Asp (contract manufactured product), γ -Glu-Val-Val (contract manufactured product), γ -Glu-Val-Glu (contract manufactured product), γ -Glu-Val-Lys (contract manufactured product), γ -Glu- γ -Glu-Val (contract manufactured product), γ -Glu-Gly-Gly (contract manufactured product), γ -Glu-Val-Phe (contract manufactured product), γ -Glu-Val-Ser (contract manufactured product), γ -Glu-Val-Pro (contract manufactured product) γ -Glu-Val-Arg (contract manufactured product), γ -Glu-Val-Asp (contract manufactured product), γ -Glu-Val-Met (contract manufactured product), γ -Glu-Val-Thr (contract manufactured product), γ -Glu-Val-His (contract manufactured product), γ -Glu-Val-Asn (contract manufactured product), γ -Glu-Val-Gln (contract manufactured product), γ -Glu-Val-Cys (contract manufactured product), γ -Glu-Val-Orn (contract manufactured product) and γ -Glu-Ser-Gly (contract manufactured product) were used. Glutamine and cysteine were prepared upon use, and the other samples were stored at -20°C after preparation. As the peptides, those having a purity of 90% or higher were used. As only for γ -Glu-Cys, one having a purity of 80% or higher was used. When the solution dissolving each sample showed an acidic or alkaline pH, the solution was adjusted to an approximately neutral pH by using NaOH or HCl. The solution used for dissolution of amino acids and peptides, preparation of *Xenopus laevis* oocytes, and culture of the oocytes had the following composition: 96 mM NaCl, 2 mM KCl, 1 mM MgCl_2 , 1.8 mM CaCl_2 , 5 mM Hepes, pH 7.2.

<Example 3>

<Synthesis of γ -Glu-Val-Gly>

[0056] Boc-Val-OH (8.69 g, 40.0 mmol) and Gly-OBzl-HCl (8.07 g, 40.0 mmol) were dissolved in methylene chloride (100 ml), and the solution was kept at 0°C . Triethylamine (6.13 ml, 44.0 mmol), HOBt (1-hydroxybenzotriazole, 6.74 g, 44.0 mmol), and WSC·HCl (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 8.44 g, 44.0 mmol) were added to the solution, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (200 ml). The solution was washed with water (50 ml), 5% citric acid aqueous solution (50 ml x twice), saturated brine (50 ml), 5% sodium hydrogencarbonate aqueous solution (50 ml x twice), and saturated brine (50 ml). The organic layer was dried over anhydrous magnesium sulfate, magnesium sulfate was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was recrystallized from ethyl acetate/n-hexane to obtain Boc-Val-Gly-OBzl (13.2 g, 36.2 mmol) as white crystals.

[0057] Boc-Val-Gly-OBzl (5.47 g, 15.0 mmol) was added to 4 N HCl/dioxane solution (40 ml), and the mixture was stirred at room temperature for 50 minutes. Dioxane was removed by concentration under reduced pressure, n-hexane (30 ml) was added to the residue, and the mixture was concentrated under reduced pressure. This procedure was repeated 3 times to quantitatively obtain H-Val-Gly-OBzl-HCl.

[0058] The above H-Val-Gly-OBzl-HCl and Z-Glu-OBzl (5.57 g, 15.0 mmol) were dissolved in methylene chloride (50 ml), and the solution was kept at 0°C . Triethylamine (2.30 ml, 16.5 mmol), HOBt (1-hydroxybenzotriazole, 2.53 g, 16.5 mmol), and WSC·HCl (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 3.16 g, 16.5 mmol) were added to the solution, and the mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in heated ethyl acetate (1500 ml). The solution was washed with water (200 ml), 5% citric acid aqueous solution (200 ml x twice), saturated brine (150 ml), 5% sodium hydrogencarbonate aqueous solution (200 ml x twice), and saturated brine (150 ml). The organic layer was dried over anhydrous magnesium sulfate, magnesium sulfate was removed by filtration, and the filtrate was concentrated under reduced pressure. The deposited crystals were collected by filtration, and dried under reduced pressure to obtain Z-Glu(Val-Gly-OBzl)-OBzl (6.51 g, 10.5 mmol) as white crystals.

EP 2 299 271 B9

[0059] The above Z-Glu(Val-Gly-OBzl)-OBzl (6.20 g, 10.03 mmol) was suspended in ethanol (200 ml), and added with 10% palladium/carbon (1.50 g), and reduction reaction was performed at 55°C for 5 hours under a hydrogen atmosphere. During the reaction, 100 ml in total of water was gradually added. The catalyst was removed by filtration using a Kiriya funnel, and the filtrate was concentrated under reduced pressure to a half volume. The reaction mixture was further filtered through a membrane filter, and the filtrate was concentrated under reduced pressure. The residue was dissolved in a small volume of water, and added with ethanol to deposit crystals, and the crystals were collected by filtration, and dried under reduced pressure to obtain white powder of γ -Glu-Val-Gly (2.85 g, 9.40 mmol). ESI-MS: $(M+H)^+ = 304.1$

$^1\text{H-NMR}$ (400 MHz, D_2O) δ (ppm): 0.87 (3H, d, $J=6.8$ Hz), 0.88 (3H, d, $J=6.8$ Hz), 1.99-2.09 (3H, m), 2.3B-2.51 (2H, m) 3.72 (1H, t, $J=6.35$ Hz), 3.86 (1H, d, $J=17.8$ Hz), 3.80 (1H, d, $J=17.8$ Hz), 4.07 (1H, d, $J=6.8$ Hz)

<Example 4>

<Synthesis of γ -Glu-Cys(S-Me)-Gly [Cys(S-Me): S-methylcysteine]>

[0060] Reduced glutathione (15.0 g, 48.8 mmol) was added to water (45 ml), and sodium hydroxide (4.52 g, 2.2 equivalents, 107 mmol) was added portionwise to the mixture while the mixture was bubbled with nitrogen. Methyl iodide (4.56 ml, 1.5 equivalents, 73 mmol) was added to the mixture, and the mixture was sealed and stirred at room temperature for 2 hours. The reaction mixture was adjusted to pH 2 to 3 with concentrated hydrochloric acid, added with ethanol (150 ml), and stored overnight in a refrigerator. Since oily matter was separated, the supernatant was removed. When the remained oily matter was dissolved in water and gradually added with ethanol, partially crystallized oily matter was deposited. Therefore, the supernatant liquid was removed again. The residue was dissolved in water (300 ml), adsorbed on an ion exchange resin (Dowex 1-acetate, 400 ml) filled in a column, and after washing with water, eluted with 1 N acetic acid aqueous solution. The eluate was concentrated under reduced pressure, and precipitated from water/ethanol to obtain a white powder of γ -Glu-Cys(S-Me)-Gly (5.08 g, 15.8 mmol).

FAB-MS: $(M+H)^+ = 322$

$^1\text{H-NMR}$ (400 MHz, D_2O) δ (ppm): 2.14 (3H, s), 2.15-2.22 (2H, m), 2.50-2.58 (2H, m), 2.86 (1H, dd, $J=9.0$ Hz, $J=14.0$ Hz), 3.03 (1H, dd, $J=5.0$ Hz, $J=14.0$ Hz), 3.89 (1H, t, $J=6.5$ Hz), 3.99 (2H, s), 4.59 (1H, dd, $J=5.0$ Hz, $J=9.0$ Hz)

<Example 5>

<Synthesis of other peptides>

[0061] γ -Glu-Met(O), γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys(S-Me)(O), γ -Glu-t-Leu, γ -Glu-Cys(S-allyl)-Gly, and γ -Glu-Cys(S-Me) were synthesized in a manner similar to those of Examples 3 and 4.

<Example 6>

<Evaluation of calcium receptor activation activity>

[0062] For evaluation of calcium receptor activation activity, a Ca ion concentration-dependent Cl ionic current measuring method using a *Xenopus laevis* oocyte expression system was used. If each activator is added to *Xenopus laevis* oocytes expressing the calcium receptor, intracellular Ca ions increase. Then, the Ca ion concentration-dependent Cl channel opens, and the intracellular current value changes as an ionic current.

[0063] By measuring the change in this intracellular current value, whether the calcium receptor activation activity is present or not can be known.

[0064] Specifically, the abdomen of *Xenopus laevis* was opened, and an egg batch was taken out and treated with a 1% collagenase solution at 20°C for 2 hours to obtain individual oocytes. Into the oocytes, 50 nl of 1 $\mu\text{g}/\mu\text{l}$ receptor cRNA or 50 nl of sterilized water per one oocyte was introduced by using a micro glass capillary, and the oocytes were cultured at 18°C for 2 or 3 days. For the culture, a solution obtained by adding 2 mM pyruvic acid, 10 U/ml of penicillin, and 10 $\mu\text{g}/\text{ml}$ of streptomycin to the solution mentioned in Example 2 was used. After the culture, a test solution was added to the oocytes introduced with cRNA or sterilized water.

[0065] Electrophysiological measurement was performed by using an amplifier, Geneclamp500 (Axon), and recording software, AxoScope 9.0 (Axon). The oocytes were voltage-clamped at -70 mV by the double electrode voltage clamp method, and the intracellular current was measured via the Ca ion concentration-dependent Cl ion channel. The maximum value of the intracellular current was considered as the response current value.

<Example 7>

<Evaluation of calcium receptor activation activity of calcium>

5 **[0066]** The calcium receptor activation activity of calcium was evaluated by using the method described in Example 6. That is, oocytes introduced with cRNA of the calcium receptor or sterilized water were prepared, and voltage-clamped at -70 mV by the double electrode voltage clamp method. To the voltage-clamped oocytes, calcium was added (2 mM, 5 mM, 10 mM, 20 mM), and Ca ion concentration-dependent Cl response current was measured. The results are shown in Fig. 1. From these results, it was confirmed that cRNA of the calcium receptor introduced into the oocytes were functionally expressed. Furthermore, since the oocytes introduced with water did not respond to even high concentration calcium, it was confirmed that the calcium receptor is not expressed in the oocytes themselves.

<Example 8>

15 <Evaluation of calcium receptor activation activity of L-amino acids>

[0067] Calcium receptor activation activity of L-amino acids was evaluated by using the method described in Example 6. That is, oocytes introduced with cRNA of the calcium receptor or sterilized water were prepared, and voltage-clamped at -70 mV by the double electrode voltage clamp method. To the voltage-clamped oocytes, alanine (10 mM), arginine (10 mM), asparagine (10 mM), aspartic acid (10 mM), cysteine (10 mM), glutamine (10 mM), glutamic acid (10 mM), glycine (10 mM), histidine (10 mM), isoleucine (10 mM), leucine (10mM), lysine (10 mM), methionine (10 mM), phenylalanine (10 mM), proline (10 mM), serine (10 mM), threonine (10 mM), tryptophan (10 mM), tyrosine (10 mM), valine (10 mM), ornithine (10 mM), taurine (10 mM), or hydroxyproline (10 mM) was added, and Ca ion concentration-dependent Cl response current was measured. The results are shown in Fig. 2. By these results, it was demonstrated that cysteine, histidine, phenylalanine, tryptophan, and tyrosine had definite calcium receptor activation activity. As for the aforementioned amino acids, the activation activity was reported in Proc. Natl. Acad. Sci. USA, 2000 Apr. 25, 97(9):4814-9.

<Example 9>

30 <Evaluation of calcium receptor activation activity of D-cysteine>

[0068] Calcium receptor activation activity of D-cysteine was evaluated by using the method described in Example 6. That is, oocytes introduced with cRNA of the calcium receptor or sterilized water were prepared, and voltage-clamped at -70 mV by the double electrode voltage clamp method. To the voltage-clamped oocytes, D-cysteine (10 mM), L-cysteine (10 mM), D-tryptophan (10 mM), or L-tryptophan (10 mM) was added, and Ca ion concentration-dependent Cl response current was measured. The results are shown in Fig. 3. By these results, it was demonstrated that D-cysteine had definite calcium receptor activation activity.

<Example 10>

40

<Evaluation of calcium receptor activation activity of peptides>

[0069] Calcium receptor activation activity of peptides was evaluated by using the method described in Example 6. That is, oocytes introduced with cRNA of the calcium receptor or sterilized water were prepared, and voltage-clamped at -70 mV by the double electrode voltage clamp method. To the voltage-clamped oocytes, γ -Glu-Cys-Gly (50 μ M), γ -Glu-Cys(SNO)-Gly (50 μ M), γ -Glu-Ala (50 μ M), γ -Glu-Gly (500 μ M), γ -Glu-Cys (50 μ M), γ -Glu-Met (500 μ M), γ -Glu-Thr (50 μ M), γ -Glu-Val (50 μ M), γ -Glu-Orn (500 μ M), Asp-Gly (1 mM), Cys-Gly (1 mM), Cys-Met (1 mM), Glu-Cys (50 μ M), Gly-Cys (500 μ M), or Leu-Asp (1 mM) was added, and Ca ion concentration-dependent Cl response current was measured. The results are shown in Fig. 4. By these results, it was demonstrated that the aforementioned peptides had definite calcium receptor activation activity.

<Example 11>

<Evaluation of calcium receptor activation activity of peptides>

55

[0070] Calcium receptor activation activity of peptides was evaluated in the same manner as that of Example 10. Each of the peptides shown in Table 2 was added to voltage-clamped oocytes at 1000 μ M, 300 μ M, 100 μ M, 30 μ M, 10 μ M, 3 μ M, 1 μ M, 0.3 μ M, and 0.1 μ M, and Ca ion concentration-dependent Cl response current was measured. The lowest

EP 2 299 271 B9

concentration with which current was detected was shown in Table 2 as the activity. From these results, it became clear that these 32 kinds of peptides had calcium receptor activation activity.

Table 2

No.	Peptide	Activity
1	γ -Glu-Met(O)	1000 μ M
2	γ -Glu-val-val	1000 μ M
3	γ -Glu-Val-Glu	1000 μ M
4	γ -Glu-Val-Lys	1000 μ M
5	γ -Glu-Val-Arg	1000 μ M
6	γ -Glu-Val-Asp	1000 μ M
7	γ -Glu-Val-Met	1000 μ M
8	γ -Glu-Val-Thr	1000 μ M
9	γ -Glu- γ -Glu-Val	1000 μ M
10	γ -Glu-Val-NH ₂	1000 μ M
11	γ -Glu-Val-ol	1000 μ M
12	γ -Glu-Ser	300 μ M
13	γ -Glu-Tau	300 μ M
14	γ -Glu-Cys(S-Me)(O)	300 μ M
15	γ -Glu-Val-His	100 μ M
16	γ -Glu-Val-Orn	100 μ M
17	γ -Glu-Leu	100 μ M
18	γ -Glu-Ile	100 μ M
19	γ -Glu-t-Leu	100 μ M
20	γ -Glu-Cys(S-allyl)-Gly*	100 μ M
21	γ -Glu-Val-Asn	30 μ M
22	γ -Glu-Gly*	30 μ M
23	γ -Glu-Val-Phe	30 μ M
24	γ -Glu-Val-Ser	30 μ M
25	γ -Glu-Val-Pro	30 μ M
26	γ -Glu-Ser-Gly*	30 μ M
27	γ -Glu-Cys<S-Me)	30 μ M
28	γ -Glu-Val-Cys	10 μ M
29	γ -Glu-Val-Gln	101 μ M
30	γ -Glu-Abu-Gly*	3 μ M
31	γ -Glu-Cys(S-Me)-Gly*	3 μ M
32	γ -Glu-Val-Gly	0.1 μ M
* Reference only		

<Example 12>

<Kokumi-imparting activity of peptides and amino acids used for the present invention>

5 **[0071]** Typical examples are selected from the peptides and amino acids, those calcium receptor activation activity was confirmed: γ -Glu-X-Gly (X represents Cys(SNO), Cys(S-allyl), Gly, Cys(S-Me), Abu, or Ser), γ -Glu-Val-Y (Y represents Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys, or Gln), γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met (O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys(S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu and γ -Glu-Cys(S-Me), and whether they have kokumi-imparting activity or not was determined by a sensory evaluation test.

10 **[0072]** The sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.05 g/dl), inosine monophosphate (0.05 g/dl), and calcium chloride (1 mM), alliin (S-allyl-cysteine sulfoxide: control experiment of Kokumi-imparting activity), γ -Glu-Cys-Gly, γ -Glu-Cys, γ -Glu-Ala, or γ -Glu-Val was mixed as a sample in an amount of 0.2 g/dl, and whether they had kokumi-imparting activity or not was determined. Sample solutions that became acidic after dissolution of the samples were adjusted to pH 6.8 to 7.2 with NaOH before use. The results are shown in Table 3.

Table 3

Kokumi-imparting activity of calcium receptor activators	
Calcium receptor activator	Kokumi-imparting activity
γ Glu-Cys-Gly*	+
γ Glu-Cys	+
γ Glu-Als	+
γ Glu-Val	+
* Reference only	

30 <Example 13>

<Kokumi-imparting activity of peptides used for the present invention>

35 **[0073]** Intensity of kokumi-imparting activity of each peptide, those calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

40 **[0074]** The quantitative sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.05 g/dl), inosine monophosphate (0.05 g/dl), and sodium chloride (0.5 g/dl), γ -Glu-Cys-Gly (glutathione), γ -Glu-Ala, γ -Glu-Met, or γ -Glu-Val was mixed as a sample in an amount of 0.1 g/dl, and intensity of kokumi-imparting activity was measured. Sample solutions that became acidic after dissolution of the samples were adjusted to pH 6.8 to 7.2 with NaOH before use. Evaluation was represented with sensory evaluation scores based on the control sample (0 point) and the sample added with glutathione (3 points), and the test was performed with n = 3. The results are shown in Table 4.

Table 4

Sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ -Glu-Cys-Gly*	0.1	3.0	3.0	Thickness, growth (mouthfulness), and continuity were enhanced.
γ -Glu-Ala	0.1	0.5	0.2	Although the effect was weak, thickness was slightly enhanced.
γ -Glu-Met	0.1	1.5	0.4	Thickness, and growth (mouthfulness) were slightly enhanced.

EP 2 299 271 B9

(continued)

Sample	Concent ration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
γ -Glu-Val	0.1	3.0	1.0	Thickness, and growth (mouthfulness) were enhanced mainly for first and middle tastes
* Reference only				

<Example 14>

<Kokumi-imparting activity of peptides used for the present invention>

[0075] Intensity of kokumi-imparting activity of each peptide, those calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0076] The quantitative sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.05 g/dl), inosine monophosphate (0.05 g/dl), and sodium chloride (0.5 g/dl), γ -Glu-Cys-Gly (glutathione), γ -Glu-Cys, γ -Glu-Val, or γ -Glu-Val-Gly was mixed as a sample in an amount of 0.1 g/dl, or 0.01 g/dl as required, and intensity of kokumi-imparting activity was measured. Sample solutions that became acidic after dissolution of the samples were adjusted to pH 6.8 to 7.2 with NaOH before use. Evaluation was represented with sensory evaluation scores based on the control sample (0 point) and the sample added with glutathione (3 points), and the test was performed with n = 5. The results are shown in Table 5.

Table 5

Sample	Concent ration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ -Glu-Cys-Gly **	0.1	3.0	3.0	Thickness, growth (mouthfulness), and continuity were enhanced.
γ -Glu-Cys	0.1	2.0	2.0	The effect was slightly weaker, but substantially equivalent compared with γ Glu-Cys-Gly
γ -Glu-Val	0.1	3.0	1.0	Thickness, and growth (mouthfulness) were enhanced mainly for first and middle tastes
γ -Glu-Val-Gly	0.1	*	*	*
γ -Glu-Val-Gly	0.01	3.0	3.0	Thickness, and continuity were mainly enhanced. Total taste was enhanced
*Unmeasurable: Kokumi-imparting activity was too strong and could not be measured by the sensory evaluation. ** Reference only				

<Example 15>

<Kokumi-imparting activity of peptides used for the present invention>

[0077] Intensity of kokumi-imparting activity of each peptide, those calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0078] The quantitative sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.05 g/dl), inosine monophosphate (0.05 g/dl), and sodium chloride (0.5 g/dl), γ -Glu-Cys-Gly (glutathione), γ -Glu-Abu-Gly, or γ -Glu-Val-Gly was mixed as a sample in an amount of 0.1 g/dl or 0.01 g/dl, and intensity of kokumi-imparting activity was measured. Sample solutions that became acidic after dissolution of the samples were adjusted to pH 6.8

EP 2 299 271 B9

to 7.2 with NaOH before use. Evaluation was represented with sensory evaluation scores based on the control sample (0 point) and the sample added with glutathione (3 points), and the test was performed with n = 12. The results are shown in Table 6.

Table 6

Sample	Concent ration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ Glu-cys-Gly *	0.1	3.0	3.0	Thickness, growth (mouthfulness), and continuity were enhanced.
γ Glu-Abu-Gly *	0.01	3.0	2.0	Thickness, and growth (mouthfulness) were enhanced mainly for first and middle tastes.
γ Glu-Val-Gly	0.01	3.0	3.0	Thickness, and continuity were mainly enhanced. Total taste was enhanced.
* Reference only				

<Example 16>

<Activity of peptides used for the present invention on basic tastes>

[0079] Intensity of activity on basic tastes of each peptide, those calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0080] The quantitative sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.2 g/dl) as a umami standard solution, sucrose (5 g/dl) as a sweet taste standard solution, sodium chloride (0.7 g/dl) as a salty taste standard solution, or citric acid (0.05 g/dl) as a sour taste standard solution, γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly was mixed as a sample at a concentration of 0.0001 to 1 g/dl, and intensity of activity on basic tastes was measured for each sample.

[0081] Sample solutions that became acidic after dissolution of the samples with respect to the standard solutions without the samples were adjusted with NaOH to pH not lower or higher by 0.2 than pH of the standard solutions before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 1 point for fairly intense activity to control, and 2 points for intense activity to control, and the test was performed with n = 12. The samples showed basic taste enhancing activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 7.

Table 7

Evaluation system	Distilled water	γ Glu-Cys-Gly* 0.10g/dl	γ Glu-Val-Gly 0.005g/dl	γ Glu-Val-Gly 0.01g/dl
Umami	0	0.7	0.7	1.5
Sweet taste	0	1.5	0.5	1.0
Salty taste	0	0.2	0.5	1.0
Sour taste	0	1.5	0.5	1.0
* Reference only				

<Example 17>

<Activity of peptides used for the present invention for imparting kokumi to consomme soup>

[0082] Intensity of activity for imparting kokumi to consomme soup of each peptide, for which calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0083] The quantitative sensory evaluation test was performed as follows. Consomme soup was prepared by dissolving

consomme soup powder (35% of sodium chloride, 18% of sodium glutamate, 0.2% of inosine monophosphate, 0.3% of white pepper powder, 0.5% of black pepper powder, 8.0% of beef extract powder, 3.0% of white wine powder, 2.0% of celery powder, 8.0% of Chinese cabbage extract powder, 2.5% of onion extract powder, 25.5% of lactose) at a concentration of 5 g/dl. To this consomme soup, γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly was mixed as a sample at a concentration of 0.0001 to 1 g/dl, and intensity of kokumi-imparting activity was measured for each sample. The consomme soup with the samples that became acidic after dissolution of the samples with respect to the consomme soup without the samples were adjusted with NaOH to pH not lower or higher by 0.2 than pH of the consomme soup without the samples before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 3 points for intense activity to control, and 5 points for extremely intense activity to control, and the test was performed with n = 12. The samples showed kokumi-imparting activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 8.

Table 8

Sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ Glu-Cys-Gly *	0.01	3.0	3.0	Thickness, growth (mouthfulness), and continuity were enhanced.
γ Glu-Val-Gly	0.0005	2.5	3.0	Thickness and growth (mouthfulness) were mainly enhanced from first and middle taste.
γ Glu-Val-Gly	0.001	3.0	3.5	Thickness and growth (mouthfulness) were mainly enhanced from first and middle taste.
γ Glu-Val-Gly	0.01	5.0	5.0	Thickness and continuity were mainly enhanced. Total taste was enhanced.
γ Glu-Val-Gly	0.1	5.0	5.0	Thickness and continuity were mainly enhanced. Total taste was enhanced.
* Reference only				

<Example 18>

<Activity of peptides used for the present invention for imparting kokumi to Japanese clear soup>

[0084] Intensity of activity for imparting kokumi to clear soup of each peptide, for which calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0085] The quantitative sensory evaluation test was performed as follows. Japanese clear soup was prepared by adding 0.5 g/dl of soy sauce and 0.6 g/dl of sodium chloride to bonito kelp stock (solution obtained by adding 5 g of dried kelp to 3 L of water, heating the water, adding 25 g of dried bonito flakes just before boiling, and then filtering the water containing kelp and bonito flakes). To this clear soup, γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly was mixed as a sample at a concentration of 0.0001 to 1 g/dl, and intensity of kokumi-imparting activity was measured for each sample. The clear soup with the samples that became acidic after dissolution of the samples with respect to the clear soup without the samples were adjusted with NaOH to pH not lower or higher by 0.2 than pH of the clear soup without the samples before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 3 points for intense activity to control, and 5 points for extremely intense activity to control, and the test was performed with n = 12. The samples showed kokumi-imparting activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 9.

EP 2 299 271 B9

Table 9

sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ Glu-Cys-Gly *	0.01	2.0	2.0	Thickness and growth (mouthfulness) were enhanced.
γ Glu-Val-Gly	0.0005	2.5	3.0	Thickness, growth (mouthfulness) and continuity were mainly enhanced from first and middle taste.
γ Glu-Val-Gly	0.001	3.5	4.0	Thickness, growth (mouthfulness) and continuity were mainly enhanced from first and middle taste.
γ Glu-Val-Gly	0.01	5.0	5.0	Thickness, and continuity were mainly enhanced. Total taste was enhanced.
γ Glu-Val-Gly	0.1	5.0	5.0	Thickness, and continuity were mainly enhanced. Total taste was enhanced.
* Reference only				

<Example 19>

<Activity of peptides used for the present invention for imparting kokumi to corn soup>

[0086] Intensity of activity for imparting kokumi to corn soup of each peptide, for which calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0087] The quantitative sensory evaluation test was performed as follows. To commercially available corn soup, γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly was mixed as a sample at a concentration of 0.0001 to 1 g/dl, and intensity of kokumi-imparting activity was measured for each sample. The corn soup with the samples that became acidic after dissolution of the samples with respect to the corn soup without the samples were adjusted with NaOH to pH not lower or higher by 0.2 than pH of the corn soup without the samples before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 3 points for intense activity to control, and 5 points for extremely intense activity to control, and the test was performed with n = 12. The samples showed kokumi-imparting activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 10.

Table 10

Sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ Glu-Cys-Gly *	0.01	3.0	3.0	Richness, thickness and growth (mouthfulness) were enhanced.
γ Glu-Val-Gly	0.0005	2.5	3.0	Sweet taste, growth (mouthfulness) and continuity were mainly enhanced from first and middle taste.
γ Glu-Val-Gly	0.001	3.5	4.0	Sweet taste, growth (mouthfulness) and continuity were mainly enhanced from first and middle taste.

EP 2 299 271 B9

(continued)

Sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
γ Glu-Val-Gly	0.01	4.5	5.0	Growth (mouthfulness) and continuity were mainly enhanced. Total taste was enhanced.
γ Glu-Val-Gly	0.1	5.0	5.0	Growth (mouthfulness) and continuity were mainly enhanced. Total taste was enhanced.
* Reference only				

<Example 20>

<Activity of peptides used for the present invention for imparting kokumi to curry sauce>

[0088] Intensity of activity for imparting kokumi to curry sauce of each peptide, for which calcium receptor activation activity was confirmed, was measured by a quantitative sensory evaluation test.

[0089] The quantitative sensory evaluation test was performed as follows. To curry sauce prepared in a conventional manner by using commercially available curry roux, γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly was mixed as a sample at a concentration of 0.0001 to 1 g/dl, and intensity of kokumi-imparting activity was measured for each sample. The curry sauces with the samples that became acidic after dissolution of the samples with respect to the curry soup without the samples were adjusted with NaOH to pH not lower or higher by 0.2 than pH of the curry soup without the samples before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 3 points for intense activity to control, and 5 points for extremely intense activity to control, and the test was performed with n = 12. The samples showed kokumi-imparting activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 11.

Table 11

Sample	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
		First and middle taste	Aftertaste	
Control	-	0	0	-
γ Glu-Cys-Gly *	0.01	3.0	3.0	Richness, thickness and continuity were enhanced.
γ Glu-Val-Gly	0.001	2.5	3.0	Mildness, richness and growth (mouthfulness) were mainly enhanced.
γ Glu-Val-Gly	0.005	3.5	4.0	Mildness, richness and growth (mouthfulness) were mainly enhanced.
γ Glu-val-Gly	0.01	5.0	5.0	Richness and continuity were mainly enhanced. Total taste was enhanced.
γ Glu-Val-Gly	0.1	5.0	5.0	Richness and continuity were mainly enhanced. Total taste was enhanced.
* Reference only				

<Example 21>

<Kokumi-imparting activity observed when peptides used for the present invention and additives such as known calcium receptor activators were used in combination>

[0090] Intensity of kokumi-imparting activity of each peptide for which calcium receptor activation activity was confirmed, used with an additive such as known calcium receptor activators in combination was measured by a quantitative sensory evaluation test.

[0091] The quantitative sensory evaluation test was performed as follows. To distilled water containing sodium glutamate (0.05 g/dl), inosine monophosphate (0.05 g/dl), and sodium chloride (0.5 g/dl), 0.0001 to 1 g/dl of γ -Glu-Cys-Gly (glutathione) or γ -Glu-Val-Gly, or either of these peptides and another calcium receptor activator (calcium lactate, protamine or polylysine) or GABA (addition concentration: 0.0001 to 1 g/dl) were mixed, and intensity of kokumi-imparting activity was measured. Sample solutions that became acidic after dissolution of the samples were adjusted to pH 6.8 to 7.2 with NaOH before use. Evaluation was represented with the following sensory evaluation scores: 0 point for control sample, 3 points for intense activity (as intensity of 0.05 g/dl γ -Glu-Cys-Gly and 0.005 g/dl γ -Glu-Val-Gly), and 6 points for extremely intense activity (as twice intensity of 0.05 g/dl γ -Glu-Cys-Gly and 0.005 g/dl γ -Glu-Val-Gly), and the test was performed with n = 12. The samples showed kokumi-imparting activity at concentrations within the aforementioned broad concentration range. The results for typical concentrations are shown in Table 12. As a result, existing compound having kokumi-imparting activity, glutathione, also show improved kokumi-imparting activity as well as kokumi-imparting agent used in the present invention when used with existing calcium receptor activator or the like such as calcium.

Table 12

Peptide sample	Concentration (g/dl)	Additive	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
				First and middle taste	After taste	
-	-	-	-	0	0	
γ Glu-cys-Gly *	0.05	-	-	3.0	3.0	Thickness, growth (mouthfulness) and continuity
γ Glu-Val-Gly	0.005	-	-	3.0	3.0	Thickness and continuity
-	-	Calcium lactate	0.25	0.5	0.5	Thickness
-	-	Protamine	0.005	1.5	1.0	Growth (mouthfulness)
-	-	Polylysine	0.001	0.5	0.5	Thickness
-	-	GABA	0.025	0.5	0.5	Thickness
γ Glu-Cys-Gly *	0.05	Calcium lactate	0.25	3.5	4.0	Thickness, growth (mouthfulness) and continuity
γ Glu-Cys-Gly *	0.05	Protamine	0.005	4.5	4.5	Thickness, growth (mouthfulness) and continuity
γ Glu-Cys-Gly *	0.05	Polylysine	0.001	3.5	4.0	Thickness, growth (mouthfulness) and continuity

(continued)

Peptide sample	Concentration (g/dl)	Additive	Concentration (g/dl)	Intensity of kokumi		Evaluation remarks
				First and middle taste	After taste	
γ Glu-cys-Gly *	0.05	GABA	0.025	4.5	4.5	Thickness, growth (mouthfulness) and continuity
γ Glu-Val-Gly	0.005	Calcium lactate	0.25	5.0	5.0	Thickness and continuity
γ Glu-Val-Gly	0.005	Protamine	0.005	4.5	4.5	Thickness, growth (mouthfulness) and continuity
γ Glu-Val-Gly	0.005	Polylysine	0.001	4.5	4.5	Thickness and continuity
γ Glu-Val-Gly	0.005	GABA	0.025	4.5	4.5	Richness and thickness
* Reference only						

Industrial Applicability

[0092] By the present invention, it has become clear that the specific amino acids and peptides having calcium receptor activation activity are also useful as kokumi-imparting substances. In particular, as shown in Examples 12 to 21, several kinds of dipeptides and tripeptides were newly discovered as kokumi-imparting substances, and since they are peptides, they can be used in the field of foodstuffs in which high safety is demanded. In addition, since a method for screening for a kokumi-imparting substance utilizing calcium receptor activation as an index has been developed, so-called high throughput screening can be used, and thus development of a still more highly efficient kokumi substance has become possible.

SEQUENCE LISTING

[0093]

<110> Ajinomoto Co., Inc.

<120> Kokumi-imparting agent

<130> C565-C6200

<150> JP2005-325300

<151> 2005-11-09

<150> US 60/738562

<151> 2005-11-22

<150> JP2006-188458

<151> 2006-07-07

<150> US 60/807831

<151> 2006-07-20

<160> 2

<170> Patent In version 3.1

<210> 1

<211> 49

<212> DNA

<213> Artificial

<220>

<223> hCASR_N primer

<400> 1

actaatacga ctactatag ggacatggc atttatagc tgctgctgg 49

<210> 2

<211> 29

<212> DNA

<213> Artificial

<220>

<223> hCASR_C primer

<400> 2

ttatgaattc actacgtttt ctgtaacag 29

Claims

1. The use of a composition comprising one or more compounds selected from the group consisting of γ -Glu-Val-Y, wherein Y is selected from the group consisting of Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys, and Gln, γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys (S-Me) (O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu and γ -Glu-Cys(S-Me), and combinations thereof, to impart kokumi on a food or drink.
2. The use according to Claim 1, wherein said compound is γ -Glu-Val-Gly.
3. The use according to Claim 1 or 2, wherein said one or more compounds are added to a food or drink at a concentration of 0.0001 to 0.1%.
4. The use according to any one of Claims 1-3, wherein a composition comprising at least one other compound having calcium receptor activation activity selected from calcium, protamine, polyarginine, spermine, polylysine, glutathione and cinacalcet is additionally added.

Patentansprüche

1. Verwendung einer Zusammensetzung, die eine oder mehrere Verbindungen, ausgewählt aus der aus γ -Glu-Val-Y, wobei Y aus der aus Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys und Gln bestehenden Gruppe ausgewählt ist, γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met(O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys (S-Me)(O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu und γ -Glu-Cys(S-Me) bestehenden Gruppe, und Kombinationen davon umfasst, um einem Nahrungsmittel oder Getränk Kokumi zu verleihen.
2. Verwendung nach Anspruch 1, wobei die Verbindung γ -Glu-Val-Gly ist.
3. Verwendung nach Anspruch 1 oder 2, wobei die eine oder die mehreren Verbindungen zu einem Nahrungsmittel oder Getränk in einer Konzentration von 0,0001 bis 0,1 % gegeben wird/werden.

4. Verwendung nach einem der Ansprüche 1 bis 3, wobei eine Zusammensetzung, die mindestens eine weitere Verbindung mit Calciumrezeptoraktivierungsaktivität, ausgewählt unter Calcium, Protamin, Polyarginin, Spermin, Polylysin, Glutathion und Cinacalcet, enthält, zusätzlich zugegeben wird.

5

Revendications

1. Utilisation d'une composition comprenant un ou plusieurs composés choisis dans le groupe consistant en γ -Glu-Val-Y où Y est choisi dans le groupe consistant en Gly, Val, Glu, Lys, Phe, Ser, Pro, Arg, Asp, Met, Thr, His, Orn, Asn, Cys et Gln, γ -Glu-Ala, γ -Glu-Gly, γ -Glu-Cys, γ -Glu-Met, γ -Glu-Thr, γ -Glu-Val, γ -Glu-Orn, Asp-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ -Glu-Met (O), γ -Glu- γ -Glu-Val, γ -Glu-Val-NH₂, γ -Glu-Val-ol, γ -Glu-Ser, γ -Glu-Tau, γ -Glu-Cys (S-Me) (O), γ -Glu-Leu, γ -Glu-Ile, γ -Glu-t-Leu et γ -Glu-Cys (S-Me), et leurs combinaisons, pour conférer kokumi à un aliment ou une boisson.
2. Utilisation selon la revendication 1 où ledit composé est γ -Glu-Val-Gly.
3. Utilisation selon la revendication 1 ou 2 où lesdits un ou plusieurs composés sont ajoutés à un aliment ou une boisson à une concentration de 0,0001 à 0,1 %.
4. Utilisation selon l'une quelconque des revendications 1-3 où une composition comprenant au moins un autre composé ayant une activité d'activation de récepteur du calcium choisi parmi le calcium, la protamine, la polyarginine, la spermine, la polylysine, le glutathion et le cinacalcet est ajouté en plus.

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2005325300 A [0001] [0093]
- JP 2006188458 A [0001] [0093]
- US 60738562 B [0001] [0093]
- US 60807831 B [0001] [0093]
- JP 1464928 A [0010]
- JP 10276709 A [0010]
- JP 8289760 A [0010]
- WO 2004096836 A [0010]
- WO 0151629 A2 [0011]
- JP 7188282 A [0012]
- EP 1554939 A1 [0013]
- WO 2004011653 A [0040]

Non-patent literature cited in the description

- *Nature*, 09 December 1993, vol. 366 (6455), 575-80 [0010]
- *J. Endocrinol.*, 16 May 2000, vol. 5 (2), 173-7 [0010]
- *Eur. J. Pharmacol.*, 05 July 2002, vol. 447 (2-3), 271-8 [0010]
- *Cell Calcium.*, 03 March 2004, vol. 5 (3), 209-16 [0010]
- *J. Agr. Food Chem.*, 1975, vol. 23 (1), 49-53 [0038]
- *Proc. Natl. Acad. Sci. USA*, 25 April 2000, vol. 97 (9), 4814-9 [0067]